Form 4: Aprea Therapeutics Director Gabriela Gruia Reports Acquisition of Shares and Stock Options

Aprea Therapeutics, Inc. Director Gabriela Gruia reported the acquisition of 1,045 restricted stock units and 4,185 stock options on June 5, 2025, aligning her interests with shareholders.

Summary

• Director Gabriela Gruia acquired 1,045 shares of common stock in the form of restricted stock units (RSUs) from Aprea Therapeutics, Inc. on June 5, 2025.
• These RSUs were granted at a price of $0.00 per share and are scheduled to vest and settle in common stock on June 5, 2026, contingent on her continued service on the board.
• Ms. Gruia also acquired 4,185 stock options with an exercise price of $1.81 per share on June 5, 2025.
• These stock options will vest in full on June 5, 2026, subject to her continued service, and have an expiration date of June 5, 2035.
• Following these transactions, Ms. Gruia directly beneficially owns 1,045 shares of common stock and 4,185 stock options.

Sentiment

Score: 7

Explanation: The acquisition of equity by a director, even if granted as compensation, generally indicates alignment of interests and a positive commitment to the company's future, which is a moderately positive signal for investors.

Positives

• Director Gabriela Gruia acquired 1,045 restricted stock units and 4,185 stock options, increasing her direct beneficial ownership in Aprea Therapeutics.
• The acquisition of equity awards aligns the director's interests with those of the shareholders, incentivizing long-term performance and value creation.

Risks

• The vesting of both the restricted stock units and stock options is contingent upon the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date.

Future Outlook

This Form 4 filing reports a past transaction of equity awards to a director and does not contain forward-looking statements or guidance regarding the company's future financial performance or strategic outlook, beyond the vesting schedule of the granted securities.

Industry Context

This document is an insider transaction report, specifically detailing equity compensation granted to a director. It does not provide information related to broader industry trends, market conditions, or competitive landscape, but rather focuses on an individual's ownership stake within the company.

Stakeholder Impact

• Shareholders: The director's increased equity ownership aligns her interests with shareholders, potentially leading to more focused decision-making for long-term value creation and improved corporate governance.

Next Steps

• The restricted stock units and stock options are scheduled to vest on June 5, 2026, subject to Director Gabriela Gruia's continued service on the board.

Key Dates

Recommendation

Keywords

Aprea Therapeutics, APRE, Form 4, Insider Transaction, Director, Stock Options, Restricted Stock Units, Equity Compensation, Beneficial Ownership